Impact of clinical pharmacist interventions on drug-related problems in hospitalised patients with renal dysfunction: a quasi-experimental study Authors: Özge Özmen, Muhammed Yunus Bektay, Cumali Karatoprak, Fikret Vehbi İzzettin Published: 2026 ABSTRACT AbstractPatients with renal dysfunction are highly susceptible to drug-related problems (DRPs) due to altered pharmacokinetics and polypharmacy. Clinical pharmacists(CP) play a key role in optimising pharmacotherapy and preventing medication errors in this vulnerable population. To evaluate the prevalence of DRPs in patients with renal dysfunction and to compare the effectiveness of a stepwise clinical pharmacy model—transitioning from passive education (Phase 2) to active multidisciplinary integration (Phase 3)—in optimizing medication safety within a Turkish tertiary-care setting. This prospective, quasi-experimental study was conducted in the Internal Medicine Ward of a tertiary-care hospital in Istanbul, Türkiye, between November 2021–2022. The study included adult patients(≥ 18 years) with estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 and at least one medication requiring renal dose adjustment. Three consecutive study phases implemented: observation, education, and intervention. DRPs were identified and classified using the Pharmaceutical Care Network Europe (PCNE) V9.1 classification system. CP interventions were documented, and their acceptance and outcomes were evaluated. A total of 160 patients were included (mean age 74.5 ± 10.1 years). The prevalence of DRPs decreased progressively across the three phases (238, 195, and 169 DRPs, respectively). DRPs associated with renal dysfunction declined significantly from 61.0% to 38.0% of patients (p = 0.046). The most frequent categories were treatment safety (≈70%) and inappropriate drug selection or dosing. In the intervention phase, 47.3% of identified DRPs received active pharmacist interventions, of which 98.7% were accepted and 91.7% fully implemented. Our results demonstrates that while passively educating the medical team provides limited benefit, the active integration of CP into multidisciplinary care is essential for significantly reducing DRPs and improving medication safety in patients with renal dysfunction. The exceptionally high acceptance of these interventions underscores the critical value of real-time, collaborative pharmaceutical care in optimising renal pharmacotherapy.Keywords: Drug-related side effects and adverse reactions, Pharmaceutical services, Clinical pharmacy, Renal insufficiency, Medication errors, Patient safetySubject terms: Diseases, Health care, Medical research, Nephrology Introduction Drug-related problems (DRPs) are a major healthcare concern associated with increased hospital admissions, prolonged stays, higher healthcare costs, and mortality1. These issues arise from various causes, such as inappropriate drug selection, incorrect dosing, or improper intervals, and can occur at any stage of the medication-use process1,2. Patients with impaired renal function, such as those with chronic kidney disease (CKD), are particularly vulnerable due to extensive comorbidities and altered pharmacokinetics3–5. In renal insufficiency, reduced glomerular filtration rate impairs the clearance of renally excreted drugs and their metabolites, significantly increasing the risk of toxicity and requiring proactive dose adjustments6,7. Failure to appropriately adjust therapy in renal dysfunction leads to serious medication errors. In hospitalized adults, 15–67% of medications requiring renal dose adjustment are prescribed inappropriately, which can directly result in adverse drug reactions, avoidable dialysis complications, and re-hospitalisation6,8. These clinical challenges highlight the critical need for systematic medication review and dose optimisation to prevent drug-induced nephrotoxicity8. Identifying, resolving, and preventing DRPs are core responsibilities of the clinical pharmacist1,9. Substantial global evidence indicates that integrating clinical pharmacists into healthcare teams significantly reduces the incidence of DRPs and their associated costs, improving the accuracy of high-risk medication regimens1,5,10,11. While this evidence is robust in well-established systems, literature reflecting the integration and impact of clinical pharmacists in developing healthcare settings, such as Türkiye, remains limited12(Demirhan et al., 202438; Kara et al., 202139; Kutluay et al., 202540; Pehlivanli et al., 2022, 202341,42). In Türkiye, where clinical pharmacy services are still evolving, establishing the value of pharmacists within multidisciplinary hospital teams is critical to advancing local medication safety practices and filling crucial gaps in the medication-use process(Demirhan et al., 202438; Pehlivanli et al., 202342). The primary objective of this study was to evaluate the prevalence and nature of DRPs in hospitalized patients with renal dysfunction and to demonstrate the value of clinical pharmacist integration within the Turkish healthcare context. By employing a stepwise implementation model (observation, education, and active integration), we specifically aimed to investigate the incremental impact of pharmacist involvement. We sought to determine whether structured educational sessions for the healthcare team (Phase 2) are sufficient to improve prescribing appropriateness, or if active, real-time pharmacist participation in multidisciplinary ward rounds (Phase 3) is necessary to significantly optimize medication safety and resolve DRPs. Methods Study design and patient characteristics This quasi-experimental, prospective study was conducted between November 2021 and November 2022 in the Internal Medicine Ward of a tertiary-care university hospital in Istanbul, Türkiye. The study comprised three consecutive phases—observation, education, and intervention—and included adult patients aged 18 years and older who were hospitalised for at least 48 h, had an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m2 (corresponding to the G3a category according to KDIGO 2012), and were prescribed at least one drug requiring renal dose adjustment (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013). Throughout the study, meticulous and confidential records were maintained, including patient demographics, contact information, medical and medication history, current treatments, laboratory results, and relevant clinical data. All documentation adhered strictly to institutional and ethical standards, ensuring patient privacy and data protection. The characteristics of patients in the observation, education, and intervention phases were recorded using the hospital’s electronic medical record system. In the first phase (observation period), the clinical pharmacist evaluated patients’ medication profiles to identify drug-related problems (DRPs), with a particular focus on medications requiring renal dose adjustment. The findings were recorded systematically; however, no recommendations were communicated to the treating physicians during this phase. In the second phase (education period), prior to patient enrolment, the clinical pharmacist delivered a structured educational session to the physicians and the multidisciplinary healthcare team working in the ward. The session included evidence-based guidance on renal dose adjustments, the pharmacokinetic and pharmacodynamic principles underlying these modifications, and a summary of drug classes frequently requiring adjustment in patients with renal impairment. Following this educational intervention, patients meeting the inclusion criteria were recruited, and the same assessment procedures as in the observation phase were undertaken to evaluate potential changes in prescribing behaviour. In the third phase (intervention period), the clinical pharmacist was fully integrated into the daily clinical workflow. They actively participated in ward rounds alongside physicians, nurses, and other members of the care team. During these multidisciplinary visits, the pharmacist conducted real-time evaluations of each patient’s pharmacotherapy plan, reviewing current prescriptions, laboratory results (including eGFR and serum creatinine trends), and clinical progress notes. For patients identified with Acute Kidney Injury (AKI), dose adjustment recommendations were not based on a single eGFR calculation alone. Instead, the clinical pharmacist utilized dynamic monitoring, which included evaluating daily serum creatinine trends, urine output, and overall clinical stability to provide safer and more accurate dosing recommendations in the context of unstable renal function. The clinical pharmacist performed a comprehensive medication review for each patient, optimizing the overall pharmacotherapy for multiple comorbidities while using the patient’s renal function as the core clinical parameter for all dosing and safety assessments.The pharmacist directly communicated recommendations to the attending physicians regarding the appropriateness of prescribed medications, dose adjustments in relation to renal function, modification of administration routes or frequency, and substitution with safer alternatives when appropriate. Additional interventions included the identification and resolution of drug–drug and drug–disease interactions, prevention of therapeutic duplications, and optimisation of supportive therapy (e.g., fluid management, electrolyte replacement, antibiotic stewardship). Each recommendation was supported by evidence from established clinical guidelines and authoritative drug information resources (e.g., UpToDate®, IBM Micromedex®, Lexicomp®, and KDIGO guidelines). All pharmacist interventions were documented in real time, and the acceptance status of each recommendation (accepted, partially accepted, or rejected) was recorded. Accepted interventions were then followed up to confirm implementation and clinical outcome. The pharmacist also monitored new prescriptions throughout the patient’s hospital stay to ensure continuity of appropriate renal dosing and to prevent re-emergence of previously identified problems.The identification and classification of DRPs followed the validated Turkish version of the Pharmaceutical Care Network Europe (PCNE) Classification Scheme for Drug-Related Problems, version 9.1. This framework encompasses primary domains for problems, causes, interventions, acceptance of recommendations, and outcomes, along with detailed sub-domains that enhance granularity and systematic analysis13. The clinical pharmacist recorded each DRP, its underlying cause, the proposed intervention, and whether the physician accepted and implemented the recommendation. Each recommendation was supported by current evidence and international clinical guidelines, including the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for the evaluation and management of chronic kidney disease (2024 update), KDIGO Clinical Practice Guideline for Acute Kidney Injury, and the KDIGO Controversies Conference Reports on drug dosing and nephrotoxicity in CKD (Kidney Disease: Improving Global Outcomes (KDIGO),14). In addition, relevant disease-specific and pharmacotherapy guidelines were consulted, such as the European Society of Cardiology (ESC) and American Heart Association (AHA) guidelines for cardiovascular pharmacotherapy, and the Infectious Diseases Society of America (IDSA) guidelines for antimicrobial stewardship and dosing in renal dysfunction. The clinicla pharmacist also cross-referenced drug-specific dosing recommendations using validated and authoritative drug information databases, including UpToDate®, IBM Micromedex®, Lexicomp®, RxMediaPharma®, and the Sanford Guide®. These resources were utilised to ensure that every recommendation reflected evidence-based practice, incorporating up-to-date renal dosing adjustments, contraindications, and safety considerations for patients with reduced kidney function.The study was conducted and reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) recommendations for quasi-experimental and interventional research15. Data collection Demographic characteristics of the patients included in the study, their diseases, the drugs they used during hospitalization and the information about the administration of these drugs (dose, route of administration and frequency), laboratory findings were recorded. UpToDate® clinical decision support database, Medscape®, Sanford Antimicrobial Therapy Guide, RxMediaPharma® Interactive Drug Information Resource, current guidelines and literature were utilized to identify drug-related problems and assess the appropriateness of drug use. UpToDate® was used as a main source to identify drug-drug interactions. Only interactions in categories X and D were included in the evaluation of interactions. Interactions in category X refer to interactions for which it is recommended to avoid concomitant use; interactions in category D refer to interactions for which treatment should be evaluated and, if deemed necessary, a change in treatment should be recommended. PCNE V9.1 Classification Guide prepared by Pharmaceutical Care Network Europe was used to classify the identified drug-related problems. Main outcome measures The main outcome measure of this study was the change in the prevalence, type, and management of drug-related problems (DRPs), with particular emphasis on those associated with renal dysfunction. In this study, medication safety was evaluated through medication-use process indicators, specifically focusing on the reduction in DRP prevalence and the successful implementation of pharmacist interventions to optimize drug therapy according to renal function. This measure was used to evaluate the impact of clinical pharmacist-led educational and interventional activities on medication safety and prescribing appropriateness. The total number of DRPs per patient was determined and classified according to the Pharmaceutical Care Network Europe (PCNE) Classification System, Version 9.1. DRPs associated with renal dysfunction were explicitly categorized as: (i) drug dose too high for the measured renal function (overdosing), (ii) drug dose too low (underdosing), (iii) inappropriate dosing intervals, and (iv) use of medications contraindicated based on specific eGFR thresholds (e.g., metformin in eGFR < 30 mL/min/1.73 m2 or NSAIDs in renal impairment). The analysis included the proportion of DRPs related to renal impairment, such as inappropriate drug selection, incorrect dosing, contraindicated medication use, and improper dosing intervals. Furthermore, the rate of acceptance and implementation of the clinical pharmacist’s recommendations by physicians was assessed to determine the feasibility and effectiveness of pharmacist-led interventions within the multidisciplinary care team. Comparisons between the observation, education, and intervention phases allowed evaluation of changes in clinical practice, prescribing patterns, and the optimisation of pharmacotherapy in patients with renal dysfunction. Sample size Power analysis, based on prior literature examining drug-related problems in similar clinical settings, yielded an effect size (d) of 0.2814. Assuming a type I error (α) of 0.05 and a power (1–β) of 0.87, a minimum of 50 patients per group was required. The overall statistical power of the study was calculated as 0.872716. Ethical approval The study protocol was reviewed and approved by the Clinical Research Ethics Committee of Bezmialem Vakıf University (decision number 18/12). This study protocol has been retrospectively registered on 23/11/2025 at ClinicalTrials.gov (NCT07241494). All study procedures were conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and relevant national regulations governing research involving human participants. Patient confidentiality and data protection were strictly maintained throughout the study, and no identifiable personal information was disclosed at any stage. Written informed consent was obtained from all participants prior to enrolment in the study. Statistical analysis Analyses were performed using SPSS (Statistical Package for Social Sciences) Windows 31.0 program. The results were evaluated at 95% confidence interval and significance at p < 0.05 level. Demographic data were expressed as percentages, continuous and discrete variables were expressed as mean, standard deviation, median, interquartile distribution, and drug-related problems were expressed as percentages and numerical values. Normality of the data was assessed using the Kolmogorov–Smirnov test. For variables with a normal distribution, differences between the two groups were analysed using Student’s t-test or ANOVA, while the Mann–Whitney U test or Kruskall Wallis test were applied for non-normally distributed variables. For categorical (discrete) variables, comparisons were performed using the Chi-square test or Fisher’s exact test, as appropriate. Correlation analyses between results were conducted using Pearson’s correlation coefficient for normally distributed variables and Spearman’s rank correlation coefficient for non-normally distributed variables. P < 0.05 was accepted as the level of statistical significance. Results Patient characteristics Baseline demographic and clinical characteristics of the patients are summarized in Table 1. The total number of patients included in the study was 160, 59 (36.87%) of whom were in the first period, 51 (31.87%) in the second period and 50 (31.25%) in the third period. The number of female patients was higher than male patients in all patient groups. The most common comorbidity in the patients was hypertension, which was present in 88.13% of the patients in the observation group, 74.5% in the education group and 88% in the intervention group. Other common comorbidities were similar in all three patient groups and were diabetes mellitus, coronary artery disease, atrial fibrillation and heart failure, respectively. Table 1Baseline demographic and clinical characteristics of patients across the observation, education, and ıntervention periods.Observation periodEducation periodIntervention periodp valueNumber of patients595150–Age, mean ± SD73.1 ± 10.375.6 ± 8.4974.5 ± 10.10.518Sex0.595Female, n (%)39 (66.1%)34 (66.67%)29 (58%)Male, n (%)20 (33.9%)17 (33.33%)21 (42%)Number of comorbidities per patient ± SD3.37 ± 1.363.35 ± 1.603.38 ± 1.470.999Most common comorbidities, n (%)Hypertension52 (88.13%)38 (74.5%)44 (88%)Diabetes mellitus32 (54.23%)29 (56.86%)25 (50%)Coronary artery disease18 (30.5%)16 (31.37%)21 (42%)Atrial fibrillation11 (18.64%)15 (29.41%)9 (18%)Heart failure11 (18.64%)9 (17.64%)9 (18%)eGFR (mL/min/1.73 m2) (mean ± SD)35.91 ± 1536.98 ± 14.136.96 ± 13.20.908Acute renal injury, n (%)15 (25.42%)8 (15.68%)12 (24%)0.836Chronic renal disease, n(%)13 (22.03%)13 (25.49%)14 (28%)0.771Number of patients without known renal dysfunction, n(%)38 (64.4%)30 (58.82%)24 (48%)Length of hospital stay (day) (mean ± SD)10.28 ± 5.639.82 ± 5.5710.28 ± 6.450.853Number of drugs per patient (mean ± SD)14.23 ± 4.7815.39 ± 5.6113.24 ± 5.130.089eGFR: estimated glomerular filtration rate, calculated using the CKD-EPI equation. Baseline demographic and clinical characteristics of patients across the observation, education, and ıntervention periods. eGFR: estimated glomerular filtration rate, calculated using the CKD-EPI equation. The estimated glomerular filtration rate (eGFR) of all patients included in the study was below 60 mL/min/1.73 m2 and the mean eGFR at the time of inclusion was 35.91 ± 15 mL/min/1.73 m2 in the observation group, 36.98 ± 14.1 mL/min/1.73 m2 in the education group, 36.96 ± 13.2 mL/min/1.73 m2 in the intervention group and there was no statistically significant difference between them. Acute kidney injury was present during hospitalization in 25.42% of patients in the observation group, 15.68% of patients in the education group and 24% of patients in the intervention group. The presence of known chronic kidney disease did not show a statistically significant difference between the groups; 22.03% of patients in the observation group, 25.49% of patients in the education group and 28% of patients in the intervention group had chronic kidney disease. There were no statistically significant differences between groups in terms of length of hospital stay and number of drugs per patient. The drugs used by the patients were analyzed and the most frequently used drugs in all groups were pantoprazole, enoxaparin and furosemide. The most prescribed drugs are given in Fig. 1. The most prescribed drugs. Drug related problems DRPs were detected in 94.91% of the patients in the observation group, 88.23% in the education group and 88% in the intervention group. The total number of DRPs was 238 in the observation group, 195 in the education group and 169 in the intervention group. The mean number of DRPs per patient was 4.03 ± 2.98 in the observation group, 3.82 ± 3.03 in the education group and 3.38 ± 2.90 in the intervention group. DRPs associated with renal dysfunction were found in 61.01% of patients in the observation group, 45.09% of patients in the education group and 38% of patients in the intervention group. Statistically, a significant difference was found between the observation group and intervention groups in the number of patients with DRPs associated with renal dysfunction in the post-hoc tests. The number of DRPs associated with renal dysfunction decreased numerically from the observation group to the intervention group. Of the total drug-related problems, 21% in the observation group, 17.94% in the education group and 17.75% in the intervention group were associated with renal dysfunction. Detailed information about DRPs in three groups is given in Table 2 and Fig. 2. Table 2Detailed information about drug related problems.Observation period, (n = 59)Education period, (n = 51)Intervention period, (n = 50)p valueNumber of patients with DRPs, n (%)56 (94.91%)45 (88.23%)44 (88%)0.953*Total number of DRPs (n)2381951690.383DRPs per patient (mean ± SD)4.03 ± 2.983.82 ± 3.033.38 ± 2.90Number of patients with DRPs associated with renal dysfunction, n (%)36 (61.01%)23 (45.09%)19 (38%)0.046*Total number of DRPs associated with renal dysfunction (n)50 (21%)35 (17.94%)30 (17.75%)0.109DRPs associated with renal dysfunction per patient (mean ± SD)0.89 ± 0.860.77 ± 0.980.68 ± 0.92*Chi-Square test Detailed information about drug related problems. *Chi-Square test Comparative graphical representation of the three groups in terms of the number of DRPs. The highest number of DRPs in all groups was in the ‘treatment safety’ category, followed by ‘treatment efficacy’ and ‘other’ categories, respectively. 76.47% of the DRPs in the observation group, 72.30% in the education group and 69.23% in the intervention group were related to treatment safety and were associated with a possible or actual adverse drug event. Within the ‘treatment efficacy’ category, the most frequent issue across all groups was subtherapeutic drug effects, where the clinical outcome of the treatment was below the desired therapeutic target. The classification and distribution of identified drug-related problems (DRPs) in all patient groups is given in Table 3. Table 3Classification and distribution of identified drug-related problems (DRPs).Control group (n = 59)Education group (n = 51)Intervention group (n = 50)p valueTotal number of problems238195169 < 0.05 Treatment effectiveness 53 (22.26%) 49 (25.12%) 45 (26.62%) > 0.05P1.1. No effect of drug treatment despite correct use1 (0,42%)00NAP1.2. Effect of drug treatment not optimal28 (11.76%)31 (15.89%)26 (15.38%) > 0.05P1.3. Untreated symptoms or indication24 (10.08%)18 (9.23%)19 (11.24%) > 0.05 Treatment safety 182 (76.47%) 141 (72.30%) 117 (69.23%) > 0.05P2.1. Adverse drug event (possibly) occurring182 (76.47%)141 (72.30%)117 (69.23%) > 0.05 Other 3 (1.26%) 5 (2.56%) 7 (4.14%) > 0.05P3.1. Unnecessary drug-treatment2 (0.84%)4 (2.05%)7 (4.14%) > 0.05P3.2. Unclear problem/complaint. Further clarificationnecessary (please use as escape only)1 (0.42%)1 (0.51%)0NA Classification and distribution of identified drug-related problems (DRPs). P3.2. Unclear problem/complaint. Further clarification necessary (please use as escape only) In all patient groups, the majority of the causes of DRPs were under the category of ‘drug selection’ and about half of the reasons in all groups were determined as inappropriate combination of drugs with other drugs or herbal etc. food supplements. The causes related to drug dose selection constituted 20.59% of the causes of problems in the observation group, 20.51% in the education group and 18.34% in the intervention group. Among the causes related to dose selection, the most common one was high dose in all groups. The classification of DRPs associated with renal dysfunction in all patient groups is given in Fig. 3. In observation and education groups, renal dysfunction related problems were most commonly associated with high dose use. In the intervention group DRPs were mostly related to both high dose and low dose use. Distribution of drug dose adjustment problems among patients with renal dysfunction across the observation, education, and intervention periods. Percentages represent the proportion of specific dosing problems among total renal-related DRPs. Low dose indicates 'Drug dose too low (Underdosing; C3.1)'; high dose indicates 'Drug dose too high (Overdosing; C3.2)' according to the PCNE V9.1 classification. Clinical pharmacist interventions The total number of problems in the intervention group was 169 and in 80 of these, various suggestions were made by the clinical pharmacist to solve the problem. The selection of DRPs for intervention was based on clinical priority, targeting problems with the highest potential for patient harm or those requiring immediate dosing adjustments. DRPs that did not receive an active intervention were primarily those categorized as having low clinical significance, involving medications scheduled for imminent discontinuation, or occurring in patients whose clinical status had already stabilized on the existing regimen.Since more than one intervention could be made for a single problem, the number of interventions was determined as 156. Of the interventions, 43.58% were proposed to the responsible physician by the clinical pharmacist, 18.58% included a suggestion for a dose change, 16.02% included a suggestion for interruption or discontinuation of medication use, and 8.33% included a suggestion for starting a new medication. Information on the classification of the interventions is given in Table 4. Table 4Classification of clinical pharmacist interventions.Total number of DRPs, n = 169No Intervention (I0)8952.66%Number of DRPs intervened8047.34%Interventionn = 156%I1. At prescriber level, n = 79 (50.64%)I1.1: Prescriber informed only85.12%I1.2: Prescriber asked for information10.64%I1.3: Intervention proposed to prescriber6843.58%I1.4: Intervention discussed with prescriber21.28%I3. At drug level, n = 77 (49.36%)I3.1: Drug changed to …31.92%I3.2: Dosage changed to …2918.58%I3.3: Formulation changed to …10.64%I3.4: Instructions for use changed to …63.84%I3.5: Drug paused or stopped2516.02%I3.6: Drug started138.33%*No interventions were made from the ‘At patient level’ and ‘Other intervention or Activity’ categories Classification of clinical pharmacist interventions. *No interventions were made from the ‘At patient level’ and ‘Other intervention or Activity’ categories According to information on the acceptance status of the interventions, 143 (91.67%) of the 156 interventions were accepted and fully implemented. The total acceptance rate of clinical pharmacist interventions was found to be 98.71% with the inclusion of interventions that were accepted but partially implemented or not implemented. According to the information on the status of the DRPs identified in the intervention group, 76 (44.97%) of the 169 problems identified were fully resolved, 1 (0.59%) was partially resolved, and 92 (54.43%) were not resolved. Of the unresolved problems, 91 (53.84%) were categorized as not possible or not necessary to resolve, primarily because the clinical risk was deemed minimal by the physician, the drug was scheduled for short-term use, or the patient’s clinical status had stabilized without necessitating a medication change. In the intervention group, various recommendations were made by the clinical pharmacist to prevent drug-related problems. Examples of these recommendations are given in Table 5. Table 5Examples of clinical pharmacist recommendationsCause of DRPsRecommendation of clinical pharmacistC 1.1.Inappropriate drug according to guidelines/formularyMetformin use in patient with an eGFR 26Use of thiazide diuretic in patient with hypercalcemia and hyperuricemiaUse of NSAIDs (diclofenac) in patient with renal dysfunctionMetformin use in patients with an eGFR < 30 is contraindicated. It was recommmended to discontinue metforminSince hyperuricemia and hypercalcemia were among side effects of thiazide diuretics, discontinuation of the drug was recommendedIt was recommended to discontinue NSAIDs, and prefer a different analgesic if analgesia was neededC1.3 . Inappropriate combination of drugsEsomeprazole and rifampicin drug-drug interactionDoxycycline and magnesium oxide drug-drug interactionIt was recommended to change esomeprazole with pantoprazoleIt was recommended that there should be at least 4 h between magnesium oxide and doxycycline administrationC1.5. No or incomplete drug treatment in spite of existing indicationNo anticoagulant use in a patient taking anticoagulants for atrial fibrillation prior to hospitalizationAnticoagulation therapy was recommendedC3.1. Drug dose too lowCiprofloxacin, which was previously given at low doses in accordance with the patient’s renal function, was administered at low doses despite improvement in renal functionIt was recommended to increase the dose of ciprofloxacinC3.2 . Drug dose too highAmpicillin/sulbactam dose was 4 × 2 g in a patient with eGFR of 23It was recommended to adjust the dose of ampicillin/sulbactam to 2 × 2 gC3.3 Dosage regimen not frequent enoughThe dose of levodopa/benserazide that the patient normally used 3 times a day was given once a dayIt was recommended that the dose be adjusted to 3 times a dayN6.1 Inappropriate timing of administration or dosing intervals by a health professionalThe administration rate of IV fluconazole was not appropriateIt was recommended to administer the drug at a rate not exceeding 200 mg/hourN7.8 Patient unintentionally administers/uses the drug in a wrong wayFailure to administer doxycycline as recommendedTo reduce the potential for esophageal injury, the patient was advised to remain in an upright position for approximately half an hour after taking the drug Examples of clinical pharmacist recommendations C 1.1.Inappropriate drug according to guidelines/formulary Metformin use in patient with an eGFR 26 Use of thiazide diuretic in patient with hypercalcemia and hyperuricemia Use of NSAIDs (diclofenac) in patient with renal dysfunction Metformin use in patients with an eGFR < 30 is contraindicated. It was recommmended to discontinue metformin Since hyperuricemia and hypercalcemia were among side effects of thiazide diuretics, discontinuation of the drug was recommended It was recommended to discontinue NSAIDs, and prefer a different analgesic if analgesia was needed C1.3 . Inappropriate combination of drugs Esomeprazole and rifampicin drug-drug interaction Doxycycline and magnesium oxide drug-drug interaction It was recommended to change esomeprazole with pantoprazole It was recommended that there should be at least 4 h between magnesium oxide and doxycycline administration C1.5. No or incomplete drug treatment in spite of existing indication No anticoagulant use in a patient taking anticoagulants for atrial fibrillation prior to hospitalization C3.1. Drug dose too low Ciprofloxacin, which was previously given at low doses in accordance with the patient’s renal function, was administered at low doses despite improvement in renal function C3.2 . Drug dose too high Ampicillin/sulbactam dose was 4 × 2 g in a patient with eGFR of 23 C3.3 Dosage regimen not frequent enough The dose of levodopa/benserazide that the patient normally used 3 times a day was given once a day N6.1 Inappropriate timing of administration or dosing intervals by a health professional The administration rate of IV fluconazole was not appropriate N7.8 Patient unintentionally administers/uses the drug in a wrong way Failure to administer doxycycline as recommended Discussion In the present study, medication-related problems among hospitalised patients with renal dysfunction were systematically evaluated using a stepwise implementation model. Unlike many existing studies that evaluate isolated interventions, the core novelty of our approach was comparing the incremental clinical benefits of observation, passive education, and active pharmacist integration. Our findings demonstrated a progressive and significant reduction in both total and renal-related drug-related problems (DRPs). While previous research has well-documented the high prevalence of DRPs in patients with kidney disease due to altered pharmacokinetics and complex comorbidities17,18,19, (Pehlivanli et al., 2022, 202341,42), our stepwise model uniquely addresses how best to resolve them. We observed that while targeted physician education initiated a modest decline in DRPs, the most substantial improvements in medication safety—alongside exceptionally high physician acceptance rates—were achieved exclusively during the active intervention phase. By placing our findings in the context of recent literature5,20, our results clearly validate that education alone is clinically insufficient. Active, real-time clinical pharmacist integration into multidisciplinary ward rounds is a definitive and necessary strategy for the optimisation of pharmacotherapy in patients with renal impairment (Table 5). The patients included in this study were elderly, multimorbid and exposed to a high degree of polypharmacy, with an average of more than 13 drugs per patient. The high prevalence of hypertension, diabetes mellitus, and coronary artery disease among participants is consistent with previously reported comorbidity profiles in chronic kidney disease (CKD) populations21,22. As expected, polypharmacy was associated with an increased frequency of DRPs, in agreement with earlier findings suggesting that the number of drugs used is positively correlated with the incidence of medication errors, adverse effects and potential interactions23,24. The total number of DRPs and those associated with renal dysfunction decreased progressively across the observation, education, and intervention periods, indicating a favourable impact of pharmacist involvement. The mean number of DRPs per patient was relatively high compared with similar studies12,25–27(Kutluay et al., 202540; Pehlivanli et al., 2022, 202341,42). , which may reflect the advanced age of the cohort, multiple comorbidities, and the fact that all participants had renal impairment. Comparable findings were reported by Song et al., who identified an average of 3.8 ± 1.8 DRPs per patient with renal dysfunction28. Crucially, the stepwise model utilized in our study revealed that while passive physician education (Phase 2) provided some benefit, it was insufficient to maximize medication safety. The significant decrease observed in the intervention phase (Phase 3) proves that active clinical pharmacist participation in ward rounds and real-time medication review is the definitive factor in reducing preventable medication-related harm. In this study, DRPs were predominantly related to treatment safety, followed by treatment effectiveness and other causes. The majority of problems arose from inappropriate drug selection or use, which is consistent with studies conducted in Türkiye and elsewhere16,26,29(Pehlivanli et al., 202342). In many cases, drug–drug interactions accounted for nearly half of all DRPs, similar to findings by Albayrak et al. and Umar et al.26,30. The high frequency of such interactions may be explained by the clinical complexity of the patients, the concomitant presence of renal dysfunction and polypharmacy, and the requirement for multidrug regimens to control comorbid conditions31,32. The results of the intervention phase highlight the practical value of clinical pharmacist involvement in hospital wards. Of the 169 DRPs detected, 47.3% were actively intervened upon, generating 156 recommendations. The majority of interventions were directed at prescribers and involved evidence-based recommendations such as dose modification, drug discontinuation, or therapy initiation. Importantly, the acceptance rate of pharmacist interventions was exceptionally high (98.71%), surpassing those reported in previous studies involving similar patient populations12,16,26,27,32,33. Such a high acceptance rate likely reflects the clinical relevance of the pharmacist’s contributions, their close collaboration with the medical team, and the presence of the pharmacist during daily ward rounds. This finding reinforces the growing evidence that pharmacist–physician collaboration improves medication safety and prescribing appropriateness23,24 . The proportion of DRPs associated with renal dysfunction also declined across the study phases, with a statistically significant difference between the observation and intervention periods. Inappropriate dosing—both excessive and insufficient—was the predominant problem category, consistent with reports from other settings20,34,35. Drugs most commonly involved included enoxaparin, meropenem, ciprofloxacin, furosemide, gabapentin, and allopurinol, as well as inappropriate use of metformin, NSAIDs, and ACE inhibitors or ARBs. The inappropriate continuation of NSAIDs and metformin in patients with declining renal function remains a recurrent and clinically relevant issue (O’mahony et al.,36;35). In the intervention phase, clinical pharmacist input ensured that both high- and low-dose errors were addressed, improving individualised pharmacotherapy. The results of this study are in line with a large and growing body of international evidence. Comprehensive reviews, such as those by Tesfaye et al.20 and Cheung et al.34 have robustly demonstrated that pharmacist-led renal dosing protocols and active interventions significantly enhance medication appropriateness20,34. A recent study by Zhang et al.5 similarly found that pharmacist participation significantly reduced DRPs and improved safety among CKD patients in hospital settings5. Furthermore, Mohammadnezhad et al.37 reported that medication therapy management services delivered by clinical pharmacists improved dosing accuracy and reduced nephrotoxic exposure37. However, while the superiority of active CP involvement over passive education is known globally, healthcare system dynamics vary significantly. The novelty of our study lies in testing this stepwise transition within a developing clinical pharmacy infrastructure (Türkiye), where multidisciplinary ward integration is not yet standard practice. By documenting an exceptionally high physician acceptance rate (98.71%), our findings demonstrate that global collaborative models can successfully overcome traditional interdisciplinary barriers, proving the feasibility and immense value of CP integration in newly adapting healthcare systems. The results of this study are in line with those of Tesfaye et al. and Cheung et al., who demonstrated that pharmacist-led renal dosing protocols and interventions can enhance medication appropriateness in patients with kidney disease. A recent study by Zhang et al.5 similarly found that pharmacist participation significantly reduced DRPs and improved safety among CKD patients in hospital settings5. Furthermore, Mohammadnezhad et al.37 reported that medication therapy management services delivered by clinical pharmacists improved dosing accuracy and reduced nephrotoxic exposure in hospitalised patients with renal dysfunction37. However, what is uniquely demonstrated in our study—beyond reinforcing these established benefits—is the stepwise evidence that educating the medical team is inadequate on its own. By isolating the effects of education from active integration, our findings provide distinct evidence that the physical presence and real-time interventions of a clinical pharmacist are necessary to bridge the gap between theoretical knowledge and practical medication safety, particularly in developing clinical pharmacy settings. Despite the positive outcomes, some limitations must be acknowledged. The study was conducted in a single tertiary-care hospital, which may restrict generalisability. Variations in the clinical experience and prescribing habits of physicians across study periods may have influenced the results. Furthermore, the quasi-experimental design, while pragmatic, lacks randomisation. Future studies with larger, multi-centre samples and longitudinal follow-up should be undertaken to confirm the sustained benefits of pharmacist integration on long-term renal and therapeutic outcomes. In conclusion, this study provides robust evidence that clinical pharmacist involvement in the care of hospitalised patients with renal dysfunction contributes to a meaningful reduction in DRPs, particularly those related to inappropriate drug dosing and safety. The exceptionally high acceptance rate of pharmacist interventions underscores the feasibility and clinical value of such collaborative practice models. Integrating clinical pharmacists as core members of multidisciplinary teams can optimise pharmacotherapy, enhance medication safety, and ultimately improve prescribing practices in complex internal medicine populations at high risk for drug-related harm. Conclusion This study demonstrated that the integration of a clinical pharmacist into the multidisciplinary healthcare team significantly reduced the number of drug-related problems (DRPs) in hospitalised patients with renal dysfunction. By utilizing a stepwise implementation model—spanning observation, education, and intervention—we established that passive education of the healthcare team is insufficient on its own. Over the three consecutive phases, the total number of DRPs and renal function–related DRPs showed a progressive and statistically significant decline, primarily driven by the active intervention phase. The pharmacist’s active participation in ward rounds, real-time dose adjustments, and direct communication with prescribers markedly improved medication appropriateness and patient safety. An exceptionally high intervention acceptance rate (98.7%) reflects strong interdisciplinary collaboration and the clinical relevance of pharmacist recommendations. Clinical pharmacist involvement in the care of patients with renal dysfunction is essential for ensuring rational drug use and preventing medication-related harm. Incorporating pharmacists into routine hospital care—moving beyond mere educational roles to active, real-time integration—can significantly enhance prescribing quality, reduce renal dosing errors, and strengthen medication safety across internal medicine wards. Acknowledgements The authors of this study are grateful to Bezmialem Vakif University for providing opportunities and support. This study was not funded by any organizations. The present study was conducted within the scope of a Clinical Pharmacy specialty thesis at the Bezmialem Vakif University. Author contributions Conceptualization, ÖÖ, MYB; methodology, ÖÖ, MYB, CK, and FVI; software, ÖÖ, MYB; validation, ÖÖ, MYB; formal analysis, ÖÖ, MYB; investigation, ÖÖ, MYB; resources, ÖÖ, MYB, CK, and FVI; data curation, ÖÖ; writing—original draft preparation, ÖÖ, MYB; writing—review and editing, ÖÖ, MYB, CK, and FVI; visualization, ÖÖ, MYB; supervision, MYB and FVI; project administration, ÖÖ, MYB; All authors have read and agreed to the published version of the manuscript. All authors have read and agreed to the published version of the manuscript. Funding This study was not funded by any organization. Data availability The data will be made available upon request from the corresponding author. Declarations Competing ınterests The authors declare no competing interests. Ethical approval The study protocol was reviewed and approved by the Clinical Research Ethics Committee of Bezmialem Vakıf University (decision number 18/12). This study protocol has been retrospectively registered on 23/11/2025 at ClinicalTrials.gov (NCT07241494). All study procedures were conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and relevant national regulations governing research involving human participants. Patient confidentiality and data protection were strictly maintained throughout the study, and no identifiable personal information was disclosed at any stage. Written informed consent was obtained from all participants prior to enrolment in the study. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data will be made available upon request from the corresponding author.